Chemoproteomics Services for Drug Discovery

Chemoproteomics is most useful when you need to move beyond indirect biology and into direct molecular evidence. In practical terms, it helps answer questions such as: Which protein is my compound engaging? Which residue is involved? How selective is this chemistry across the proteome? Are there ligandable or reactive sites worth pursuing in a difficult target class? For many discovery teams, those are exactly the questions that determine whether a program moves forward, changes direction, or expands into a broader profiling effort.

That makes chemoproteomics valuable across target identification, site-level mechanism work, selectivity assessment, and early covalent discovery. It is not one fixed assay. It is a family of mass spectrometry-based strategies that can be routed according to the project goal, from activity-state profiling to photoaffinity capture to residue-centric mapping.

The main advantage is not simply that chemoproteomics generates more data. The real advantage is that it generates the right kind of data for the next decision. Instead of staying at the level of phenotype, pathway change, or indirect target hypotheses, your team can work with target-level, site-level, and competition-aware outputs that are far easier to use in a drug discovery setting.

From target identification to site-level evidence

Some projects need to know which protein is engaged. Others need to know where the interaction occurs or whether one reactive chemotype behaves differently from another. Chemoproteomics gives us a route for both types of questions, which is why it is especially valuable for complex discovery programs.

Why chemoproteomics matters when functional data is not enough

A biological response does not automatically prove direct target engagement. At the same time, a weak phenotypic readout does not necessarily mean the chemistry is not worth pursuing. Chemoproteomics adds a direct molecular layer that helps separate those possibilities.

Where it fits in modern drug discovery

Chemoproteomics is especially relevant when you are working with covalent inhibitors, probes, fragment-derived chemotypes, target deconvolution problems, or projects where selectivity and ligandability matter as much as simple activity readouts.

Conventional validation methods still matter, but they often leave important gaps. Pull-down experiments, Western blot follow-up, and phenotype-led validation can all be informative, yet they may not show how broadly a chemistry behaves, which residues are involved, or whether the observed biology truly aligns with a direct engagement event.

We use chemoproteomics when those gaps begin to affect project decisions. If your team is asking whether a probe is truly selective, whether a covalent warhead is engaging the expected residue class, or whether a target deconvolution workflow can be grounded in proteome-scale evidence, chemoproteomics is often the most direct next step.

We offer chemoproteomics as a route-matched platform rather than a single fixed workflow. That matters because the best method depends on the project question, the chemistry, the sample context, and the kind of evidence your team actually needs.

Our chemoproteomics scope currently covers multiple routes that can be aligned with target identification, site mapping, selectivity assessment, ligandability discovery, and covalent chemistry programs.

The most important question on this page is not "What is chemoproteomics?" It is "Which chemoproteomics route actually fits my project?" Different methods solve different problems, and choosing the wrong one can slow a program down even when the experiment itself works technically.

ABPP-MS for activity-state and competitive engagement questions

Choose ABPP-MS when the project centers on active-state proteins, competitive probe displacement, or enzyme-directed profiling.

Photoaffinity labelling for target deconvolution and interaction capture

Choose PAL-MS when target deconvolution or interaction capture in a biologically complex system is the main challenge.

Reactive residue profiling and ligandability mapping for site-level discovery

Choose Reactive Residue Profiling or Ligandability Mapping when the key output needs to be residue-aware rather than only target-aware.

Covalent fragment screening and SuFEx chemoproteomics in reactive chemistry programs

Choose Covalent Fragment Screening or SuFEx Chemoproteomics when the chemistry itself is central to the project design.

In some projects, chemistry design is just as important as sample type. That is why sample planning and route selection should be discussed together, not separately.

Disclaimer: All products and services provided by Creative Proteomics are for research use only. They are not intended for use in diagnostic, therapeutic, or clinical procedures.